Zusammenfassung
Die Überexpression des Enzyms Transketolase-like-1 (TKTL1) korreliert sowohl bei
Kolonkarzinomen und Glioblastomen als auch bei Blasen-, Ovarial-, Larynx- und
Lungenkarzinomen mit verkürzten Überlebenszeiten. Durch eine Hemmung dieses Enzyms
lässt sich sowohl in vitro als auch in vivo im Mausmodell eine Suppression von
Tumorwachstum und Metastasenbildung erreichen. Die vorliegenden beiden Fallbeschreibungen
berichten beispielhaft über den erfolgreichen Einsatz der auf den TKTL1-Stoffwechsel
ausgerichteten Ernährungsumstellung nach dem Coy-Prinzip, mit der sich das Tumorwachstum
kontrollieren ließ.
Summary
The over-expression of the enzyme Transketolase-like 1 (TKTL1) is strongly correlated
to reduced survival rates in all types of cancer, which have to date been investigated,
such as colon cancer, glioblastoma, bladder, ovarian, larynx and lung carcinoma.
It could be shown in vitro as well as in studies with mice which were inoculated
with human cancer cells, that the growth of the tumors could be effectively suppressed
by the inhibition of the enzyme TKTL1. The present paper reports two cases (concerning
a glioblastoma and a colon cancer) as examples, in which the application of the
TKTL1-nutrition according to the Coy principle leads to a successful control of
the cancer growth.
Schlüsselwörter
Kolonkarzinom - Glioblastom - TKTL1 - TKTL1-Ernährung - Coy-Diät - Coy-Prinzip - Warburg-Hypothese
- Krebsdiät
Keywords
Colon cancer - glioblastoma - TKTL1 - TKTL1-nutrition - Coy-diet - Coy-principle -
Warburg-hypothesis - cancer diet
Literatur
- 01
Coy J F, Dressler D, Wilde J, Schubert P.
Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative
diseases, diabetes and cancer.
Clin Lab.
2005;
51
257-273
- 02
Dimitriu C, Martignoni M E, Bachmann J, Fröhlich B, Tintarescu G, Buliga T, Lica I,
Constantinescu G, Beuran M, Friess H.
Clinical impact of cachexia on survival and outcome of cancer patients.
Rom J Intern Med.
2005;
43
(3-4)
173-185
- 03
Gillies R J, Gatenby R A.
Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis?.
J Bioenerg Biomembr.
2007;
- 04
Gottfried E, Kunz-Schughart L A, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R,
Mackensen A, Kreutz M.
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.
Blood.
2006;
107
(5)
2013-2021
- 05
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S,
Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R,
Krause S W, Kreutz M.
Inhibitory effect of tumor cell derived lactic acid on human t cells.
Blood.
2007;
109
(9)
3812-3819
- 06
Kayser G, Kubitz B, Sienel W, Mattern D, Coy J, Passlick B, Werner M, Hausen A zur.
Overexpression of transketolase L1 (TKTL1) in primary non small cell lung cancer
predicts poor patient outcome and is an important potential therapeutic target.
Pathol Res Pract.
2007;
203
(5)
388
- 07
Krockenberger M, Honig A, Rieger L, Coy J F, Sutterlin M, Kapp M, Horn E, Dietl J,
Kämmerer U.
Transketolase-like 1 expression correlates with subtypes of ovarian cancer and
the presence of distant metastases.
Int J Gynecol Cancer.
2007;
17
101-106
- 08
Langbein S, Zerilli M, Hausen A zur, Staiger W, Rensch-Boschert K, Lukan N, Popa1 J,
Ternullo M P, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, Stassi G, Schubert P,
Coyl J F.
Expression of transketolase TKTL1 predicts colon an urothelial cancer patient
survival: Warburg effect reinterpreted.
British Journal of Cancer.
2006;
94
(4)
578-585
- 09
Otto C, Kämmerer U, lllert B, Mühling B, Thiede A, Coy J F.
Metabolic growth control of human TKTL1-positive tumours in nude mice with a
ketogenic diet.
TumorBiol.
2007;
28
(S 1)
18
- 10
Rais B, Comin B, Puigjaner J, Brandes J L, Creppy E, Saboureau D, Ennamany R, Lee W N P,
Boros L G, Cascante M.
Oxithiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's
tumor cells through inhibition of the pentose cycle.
FEBS letters.
1999;
456
113-118
- 11
Sattler U G A, Walenta S, Mueller-Klieser W.
Laktat und Redoxstatus in malignen Tumoren.
Der Anästhesist.
2007;
5
38-41
- 12
Staiger W I, Coy J F, Grobholz R, Hofheinz R D, Lukan N, Post S, Schwarzbach M H,
Willeke F.
Expression of the mutated transketolase TKTL1, a molecular marker in gastric
cancer.
Oncol Rep.
2006;
16
(4)
657-661
- 13
Stern R, Shuster S, Neudecker B A, Formby B.
Lactate Stimulates Fibroblast Expression of Hyaluronan and CD44: The Warburg
Effect Revisited.
Experimental Cell Research.
2002;
276
24-31
- 14
Völker H U. et al .
Overexpression of transketolase TKTL1 is associated with shorter survival in
laryngeal squamous cell carcinomas.
Eur Arch Otorhinolaryngol.
- 15 Walenta S. et al .Lactate: Mirror and motor of tumor malignancy. Seminars in Radiation
Oncology 2004 14: 267-274
- 16
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad E K, Mueller-Klieser W.
High Lactate Levels Predict Likelihood of Metastases, Tumor Recurrence, and
Restricted Patient Survival in Human Cervical Cancers.
Cancer Res.
2000;
60
916-921
- 17
Westman E C, Feinman R D, Mavropoulos J C, Vernon M C, Volek J S, Wortman J A, Yancy W S,
Phinney S D.
Low-carbohydrate nutrition and metabolism.
The American Journal of Clinical Nutrition..
2007;
86
276-284
- 18
Xu R, Pelicano H, Zhou Y, Carew J S, Feng L, Bhalla K N, Keating M J, Huang P.
Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug
Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia.
Cancer Res.
2005;
65
(2)
- 19
Zhou W, Mukherjee P, Kiebish m A, Markis M T, Mantis J G, Seyfried T N.
The calorically restricted ketogenic diet, an effective alternative therapy
for malignant brain cancer.
Nutrition & Metabolism.
2007;
2007
5
Korrespondenzadresse
Dr. med. Beate Wegener
Medizinische Beratung TAVARLIN
Heidelberger Landstr. 190
64297 Darmstadt
Phone: 0 61 51-6 66 80 38
Email: beratung@tavarlin.de
URL: http://www.tavarlin.de
Dr. med. Markus Pfisterer
Nordstr. 28
74076 Heilbronn
Phone: 0 71 31-20 45 75
Email: info@drpfisterer.de
